Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

BACKGROUND: The tumour–stroma ratio (TSR) has proven to be an independent prognostic factor in colon cancer. METHODS: Haematoxylin eosin tissue slides of patients from the AVANT trial were microscopically scored for TSR and categorised as stroma -low or stroma -high. Scores were correlated to the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zunder, Stéphanie M., van Pelt, Gabi W., Gelderblom, Hans J., Mancao, Christoph, Putter, Hein, Tollenaar, Rob A., Mesker, Wilma E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048031/
https://www.ncbi.nlm.nih.gov/pubmed/29755119
http://dx.doi.org/10.1038/s41416-018-0083-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048031/
https://www.ncbi.nlm.nih.gov/pubmed/29755119
http://dx.doi.org/10.1038/s41416-018-0083-0

Ejemplares similares